Journal
NEUROSURGERY
Volume 88, Issue 6, Pages 1056-1064Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/neuros/nyaa584
Keywords
Adoptive therapy; Chimeric antigen receptor (CAR) T cell; Clinical trials; Immunotherapy; Glioblastoma multiforme; Review
Categories
Ask authors/readers for more resources
CAR T-cell therapy, utilizing genetically engineered cells from patients to target tumor cells, has emerged as a promising strategy for treating GBM. Ongoing clinical trials are exploring the potential of this approach to combat the challenges associated with GBM treatment.
Glioblastoma multiforme (GBM) are the most common and among the deadliest brain tumors in adults. Current mainstay treatments are insufficient to treat this tumor, and therefore, more effective therapies are desperately needed. Immunotherapy, which takes advantage of the body's natural defense mechanism, is an exciting emerging field in neurooncology. Adoptive cell therapy with chimeric antigen receptor (CAR) T cells provides a treatment strategy based on using patients' own selected and genetically engineered cells that target tumor-associated antigens. These cells are harvested from patients, modified to target specific proteins expressed by the tumor, and re-introduced into the patient with the goal of destroying tumor cells. Here, we review the history of CAR T-cell therapy, and describe the characteristics of various generations of CAR T therapies, and the challenges inherent to treatment of GBM. Finally, we describe recent and current CAR T clinical trials designed to combat GBM.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available